.png)
Resilience Announces Long-Term Financing of up to $825 Million to Accelerate CDMO Strategy
New Capital from Oak Hill Advisors to Drive Investment in Go-Forward Manufacturing Operations CINCINNATI--(BUSINESS WIRE)--National Resilience...
BLOG
Read on
%201.png)
Navigating the Evolving Landscape of Fill/Finish: Trends, Challenges, and What’s Ahead
A Q&A with Nithin Stephen As the pharmaceutical and biotech industries continue to innovate at a rapid pace, the demand for fill/finish capabilities...
Redefining CAR-T Speed and Strength with DAR-T™: A Conversation with Nicholas Kirian
In this Q&A, Nicholas Kirian, Senior Manager of MSAT, discusses how DAR-T™, an autologous CAR-T platform, is addressing longstanding challenges in...
Cell Therapy Innovations: Reducing Costs to Improve Patient Access
Cell therapies offer life-changing treatments for patients with limited options, but face commercialization challenges due to high costs, ability to...
Presentation: Rapid Multi-Omics Cell Therapy Characterization and QC
On February 5th at 1:00 pm, join Neeraj Salathia, Director of Advanced Genomics, for a presentation on Rapid Multi-Omics Cell Therapy...
Whitepaper: 3-Day Short Cycle CAR-T Manufacturing Process
The conventional manufacturing process for the generation of activated CAR-T cells can typically take 7 to 9 days or even longer. Resilience has...
Presentation: Expedited Cell Therapy QC: Sample in, to QC Report in 48 Hours
On January 22nd at 4:00 pm, join Mazen Karaman, Director of Platform Management – Cell Therapy, for a presentation on Expedited Cell Therapy QC.
Accelerating Clinical Timelines of Induced Pluripotent Stem Cells (iPSCs) with Pluristyx
Resilience and Pluristyx have entered a strategic collaboration to accelerate and simplify the transition of promising iPSC-derived therapies from...
